DCVC

Grove Biopharma is a biotechnology company specializing in materials science solutions for peptide therapeutics. It focuses on discovering and developing novel 'protein-like polymers' to address significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Our full-stack tech­nol­o­gy plat­form brings micro­bio­me drug dis­cov­ery into focus. Our spa­tial map­ping dis­cov­ery engine pro­vides stun­ning pic­tures of the inter­ac­tions and con­nec­tions between host and the micro­bio­me; an area of this vital sys­tem that we’ve nev­er been able to com­plete­ly under­stand before. Spa­tial biol­o­gy of the host-micro­bio­me inter­face pro­vides new oppor­tu­ni­ties for effec­tive ther­a­peu­tic inter­ven­tions, ulti­mate­ly enabling us to bet­ter treat patients.

Latus Bio is a biotechnology company dedicated to developing innovative gene therapies for neurological diseases. It specializes in novel discovery approaches using non-human primate models, enabling precise delivery of therapeutic genes to targeted cells within the central nervous system. Latus Bio aims to enhance clinical safety and manufacturing efficiency by administering low doses of its proprietary adeno-associated virus (AAV) capsids.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Our full-stack tech­nol­o­gy plat­form brings micro­bio­me drug dis­cov­ery into focus. Our spa­tial map­ping dis­cov­ery engine pro­vides stun­ning pic­tures of the inter­ac­tions and con­nec­tions between host and the micro­bio­me; an area of this vital sys­tem that we’ve nev­er been able to com­plete­ly under­stand before. Spa­tial biol­o­gy of the host-micro­bio­me inter­face pro­vides new oppor­tu­ni­ties for effec­tive ther­a­peu­tic inter­ven­tions, ulti­mate­ly enabling us to bet­ter treat patients.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Stemson Therapeutics is a cell therapy company focused on restoring natural hair by generating new hair follicles. It uses induced pluripotent stem cells to create dermal papilla cells and combines them with a tissue engineering approach to produce a net new supply of hair follicles for patients experiencing hair loss. The company develops its proprietary methods to engineer cells capable of regenerating follicles, aiming to address emotional and social impact of hair loss. Founded in 2018, it is based in La Jolla, California.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Orca Bio is a clinical-stage cell therapy company focused on providing curative treatments for patients with various malignant and autoimmune diseases. The company has developed a range of proprietary technologies aimed at replacing diseased blood and immune systems with healthy ones. By specializing in the research and development of innovative cell therapies, Orca Bio seeks to transform the landscape of bone marrow transplantation. Its advanced therapeutic platform is designed to empower healthcare professionals in effectively treating patients, thereby addressing a significant unmet medical need. The company is backed by a team of leading experts and technologists committed to realizing its vision of delivering life-saving medical solutions.

AbCellera is an antibody discovery and development company that addresses conventional barriers to find optimal clinical candidates swiftly and efficiently. Its integrated platform combines diverse antibodies, expert selection, proprietary tools, and advanced data science to deliver developable leads quickly, setting partners up for long-term success.

AbCellera is an antibody discovery and development company that addresses conventional barriers to find optimal clinical candidates swiftly and efficiently. Its integrated platform combines diverse antibodies, expert selection, proprietary tools, and advanced data science to deliver developable leads quickly, setting partners up for long-term success.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

C16 Biosciences develops palm oil alternatives through microbial fermentation, producing high-performance lipids and oils to replace palm-derived ingredients in food, beauty, and consumer products. Using its fermentation platform, the company aims to deliver sustainable ingredients without conventional palm oil supply chains, reducing environmental impact. It markets Palmless, a platform for sustainable ingredients, and has introduced Torula oil, a bioactive oil with reported benefits for skin and hair health. Founded in 2017 and based in New York, C16 Biosciences serves food manufacturers, refiners, traders, and brands by providing reliable, environmentally friendly ingredients across beauty, personal care, home care, and food markets.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Empirico is a biotechnology company focused on developing an insights platform that leverages biological data derived from human genetics to facilitate the creation of new medicines. The platform integrates extensive biological datasets and employs programmable biology to enhance target discovery and development processes. This enables researchers to systematically generate, analyze, and prioritize therapeutic hypotheses with a high degree of confidence, thereby advancing the search for innovative treatments. Through its technology, Empirico aims to transform the landscape of drug development by providing actionable insights that can lead to effective medical solutions.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Empirico is a biotechnology company focused on developing an insights platform that leverages biological data derived from human genetics to facilitate the creation of new medicines. The platform integrates extensive biological datasets and employs programmable biology to enhance target discovery and development processes. This enables researchers to systematically generate, analyze, and prioritize therapeutic hypotheses with a high degree of confidence, thereby advancing the search for innovative treatments. Through its technology, Empirico aims to transform the landscape of drug development by providing actionable insights that can lead to effective medical solutions.

AbCellera is an antibody discovery and development company that addresses conventional barriers to find optimal clinical candidates swiftly and efficiently. Its integrated platform combines diverse antibodies, expert selection, proprietary tools, and advanced data science to deliver developable leads quickly, setting partners up for long-term success.

C16 Biosciences develops palm oil alternatives through microbial fermentation, producing high-performance lipids and oils to replace palm-derived ingredients in food, beauty, and consumer products. Using its fermentation platform, the company aims to deliver sustainable ingredients without conventional palm oil supply chains, reducing environmental impact. It markets Palmless, a platform for sustainable ingredients, and has introduced Torula oil, a bioactive oil with reported benefits for skin and hair health. Founded in 2017 and based in New York, C16 Biosciences serves food manufacturers, refiners, traders, and brands by providing reliable, environmentally friendly ingredients across beauty, personal care, home care, and food markets.

Orca Bio is a clinical-stage cell therapy company focused on providing curative treatments for patients with various malignant and autoimmune diseases. The company has developed a range of proprietary technologies aimed at replacing diseased blood and immune systems with healthy ones. By specializing in the research and development of innovative cell therapies, Orca Bio seeks to transform the landscape of bone marrow transplantation. Its advanced therapeutic platform is designed to empower healthcare professionals in effectively treating patients, thereby addressing a significant unmet medical need. The company is backed by a team of leading experts and technologists committed to realizing its vision of delivering life-saving medical solutions.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Asimov designs and develops biologics and gene therapies, focusing on mammalian cell engineering and genetic circuit design. The company combines synthetic biology, computer-aided design, and machine learning to accelerate the design and manufacture of biologics, viral vectors, and cell and gene therapies. Its platform integrates biophysical simulations with data-driven models of biology to engineer genetic circuits and optimize production processes. Founded in 2017 and based in Cambridge, Massachusetts, Asimov supports healthcare firms in advancing therapeutic pipelines through software and engineering tooling that bridges biology and computational design.

Enzyme develops cloud-based software for life sciences companies to streamline FDA approval processes and regulatory compliance. Its platform automates workflows, reduces compliance costs by up to 50%, lowers headcount related to regulatory issues, and accelerates product market entry.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Sequence Bio is a biotechnology company focused on advancing drug discovery and development through genome therapy. Leveraging the unique genetic characteristics of isolated populations, particularly those in Newfoundland, the company collects DNA and health information to enhance the identification of drug targets. This approach aims to improve the treatment of complex and inherited diseases, ultimately addressing the high failure rate of drug candidates and expediting access to effective therapies for patients in need. By utilizing genetic insights, Sequence Bio seeks to transform the landscape of medicine and deliver better health outcomes.

3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.

Capella BioScience is engaged in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAbs targeting oncology, autoimmune diseases, and other medical conditions. Capella BioScience collaborates with biotechnology firms and academic institutions to enhance its research and development efforts, aiming to advance innovative therapeutic solutions in the medical field.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

One Codex is a data platform focused on applied microbial genomics, offering bioinformatics solutions that facilitate advancements in clinical diagnostics, food safety, and biosecurity. The company specializes in developing a robust and scalable bioinformatics platform that streamlines metagenomics and microbial genomics analysis. Emphasizing user-friendliness, One Codex provides applied microbiologists with rapid access to microbiome analysis through its comprehensive microbial reference database. This approach allows researchers and professionals to leverage genomic data effectively, enhancing their ability to address challenges in various sectors related to microbiology.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Metabiota, Inc. is a San Francisco-based company founded in 2008 that specializes in assessing and investigating infectious disease threats. The company employs pathogen discovery, disease detection, and threat characterization to provide data, analytics, and strategies aimed at reducing and preventing infectious disease outbreaks. Metabiota’s platform allows local authorities and organizations to prepare mitigation strategies and manage complex infectious disease risks effectively. By offering surveillance, recognition, and diagnosis of microbial threats, Metabiota plays a critical role in helping governments and corporations track and respond to global health challenges. Through its strategic global presence and partnerships, the company is dedicated to mitigating the impacts of epidemic threats.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Moleculo is a biotechnology company specializing in innovative DNA sequencing technologies. It has created a novel sequencing method that delivers long and accurate reads, significantly enhancing the efficiency and precision of various DNA sequencing applications. This advancement allows clients to explore a broader range of applications within genomic analysis, positioning Moleculo as a key player in the biotechnology sector focused on improving genomic tools and methodologies.